CMB International Securities | Equity Research | Company Update



招商银行全资附属机构 A Wholly Owned Subsidiary Of China Merchants Bank

Xtep (1368 HK)

An impressive 4Q20 to drive further re-rating

We are impressed by Xtep's 4Q20 performance with a faster than peers growth and healthier inventory level. Therefore, we find its risk reward attractive and expect a further re-rating. Maintain BUY and raise TP to HK\$5.09, based on 14x FY22E P/E (rolled over from 13x FY21E). It is trading at 14x/11x FY21E/22E P/E.

- 4Q20 retail sales growth beat, driven by greater brand upgrades. Xtep reported a HSD core brand retail sales growth in 4Q20, beating CMBI's est. of 5% YoY, which accelerated from MSD in 3Q20 and even faster than Anta's LSD growth. Apart from earlier and colder winter, Xtep had carried out series of upgrades on marketing, products, e-commerce and offline stores. For example: 1) its style of marketing approach during double 11 was much younger than before, 2) it had launched more Chinese culture products (e.g. Tiancheng series/天乘系列) and crossovers (e.g. Xtep x Shaolin / 特步 x 少林), 3) opened more flagship stores (e.g. "X-STREET" in Xiamen and Xtep's 9th generation format store in Shenzhen).
- Inventory days improved despite stable retail discounts in 4Q20. We are impressed once again because despite retail discount of 30% to 35% (same as 3Q20), Xtep managed to have its inventory level improved to less than 5 months (vs ~5 months in 3Q20), which is better than Anta's ~5 months.
- But we believe business is still tough for K-swiss and Palladium. As second wave in COVID-19 continues to linger in EU and US, K-swiss and Palladium, which have a much less e-commerce penetration, are likely to suffer more than other leading brands. As a result, for FY20E, we now expect larger sales drop at 31% YoY (vs 22% previously) but losses to stay at US15mn (~RMB 100mn) due to more severe costs saving measures.
- Chance for Xtep's valuation to catch up. We agree that Xtep should have a discount in valuation (vs Anta and Li Ning), as it has a smaller market share, a weaker financial position and a slower growth (vs mainly FILA and Li Ning). However, given its better-than-industry performance in 4Q20, we think the historical high level of discounts at ~70% (vs 5 years avg. of 50%) is not justified. Hence, we will not be surprised to see the discounts narrowing to ~50%, if core brand's fundamental continues to improve in FY21E.
- Maintain BUY and raised TP to HK\$ 5.09. We adjusted our FY20E/ 21E/ 22E EPS estimates by -1%/ +5%/ +6%, to factor in a worse-than-expected K&P sales decline and a faster Xtep core brand sales. Given attractive valuation of 14x/ 11x FY21E/ 22E P/E, we maintain BUY and raised the TP to HK\$ 5.09, based on 14x FY22E P/E (rolled over from 13x FY21E).

Earnings Summary

(YE 31 Dec)	FY18A	FY19A	FY20E	FY21E	FY22E
Revenue (RMB mn)	6,383	8,183	8,109	9,252	10,204
YoY growth (%)	24.8	28.2	(0.9)	14.1	10.3
Net income (RMB mn)	657	728	446	617	810
EPS (RMB)	0.295	0.302	0.179	0.248	0.325
YoY growth (%)	60.6	2.3	(40.7)	38.3	31.4
Consensus EPS (RMB)	n/a	n/a	0.192	0.270	0.322
P/E (x)	11.3	11.3	19.0	13.8	10.5
P/B (x)	1.4	1.2	1.2	1.2	1.1
Yield (%)	5.2	5.2	3.2	4.4	5.7
ROE (%)	12.3	11.8	6.4	8.5	10.7
Net gearing (%)	Net cash				

Source: Company data, Bloomberg, CMBIS estimates

BUY (Maintain)

Target Price HK\$5.09 (Previous TP HK\$3.63) Up/Downside +33.7% Current Price HK\$3.81

China Sportswear Sector

Walter Woo

(852) 3761 8776 walterwoo@cmbi.com.hk

Stock Data

Mkt Cap (HK\$ mn)	9,704
Avg 3 mths t/o (HK\$ mn)	27.14
52w High/Low (HK\$)	4.45/2.04
Total Issued Shares (mn)	2,547.0
Source: Bloomberg	

Shareholding Structure

Shareholding Structure	
Mr Ding Shui Po & Family	53.89%
Templeton Investments	2.62%
Employee incentive scheme	4.01%
Free Float	39.48%
Source: HKEx	

Share Performance

Silale Fell	Ulliance	
	Absolute	Relative
1-mth	21.3%	13.3%
3-mth	35.1%	15.3%
6-mth	63.5%	43.6%
12-mth	-1/1 2%	-12 7%

Source: Bloomberg

12-mth Price Performance



Source: Bloomberg

Auditor: Ernst & Young

Related Reports

- Xtep (1368 HK, BUY) Core brand's recovery to drive re-rating - 12 Nov
 2020
- Xtep (1368 HK, HOLD) Better retail trend drags by lower margins - 31 Aug 2020
- Xtep (1368 HK, HOLD) Recovery may take longer than expected - 14 Jul 2020



Operating numbers

Figure 1: Sportswear brands sales growth trend


Operating numbers	1Q18	2Q18	3Q18	4Q18	1Q19	2Q19	3Q19	4Q19	1Q20	2Q20	3Q20	4Q20E	1Q21E	2Q21E	3Q21E	4Q21E
Operating numbers Nike China sales	19.0%	25.0%	20.0%	31.0%	24.0%	22.0%	27.0%	23.0%	-4.0%	1.0%	8.0%	19.0%	TQZTE	ZQZTE	3Q21E	4Q21E
Adidas China sales	26.0%	27.0%	26.0%	23.0%	16.0%	14.0%	11.0%	15.0%	-58.0%	0.0%	-5.0%	13.070				
Anta brand's SSSG																
Anta brand's retail sales	+ve 20%- 25%	+ve Low- teens	+ve Mid- teens	+ve Mid- teens	+ve Low- teens	+ve Mid- teens	+ve Mid- teens	+ve High- teens	-ve 20%- 25%	-ve LSD	+ve LSD	+ve LSD	32.0%	6.0%	3.0%	2.0%
Core brand	+ve Mid-	+ve HSD	+ve Low-	+ve HSD	+ve HSD	+ve Low-	+ve Low-	+ve HSD	-ve 20%- 25%	-ve LSD	-ve MSD	-ve MSD				
Kids	teens over 40%	over 25%	teens Over 25%	Over 25%	Over 20%	teens 30%	teens Over 25%	25%	-ve 20%-	+ve MSD	+ve Low-	-ve Low-				
Online			Over 20%		+ve Mid-	25%		Over 40%	25% +ve MSD		teens Over 50%	teens Over 25%				
			+ve 90%-		teens +ve 65%-		0070	0101 4070	140 1400	O VCI 4070	O VC1 00 70	0 101 2070				
Non-Anta brands (FILA)	85%	95%	95%	85%	70%	60%										
FILA brand's retail sales	;						50%-55%	50%-55%	-ve MSD	+ve Low- teens	20%-25%	25%-30%	45.0%	16.0%	12.0%	10.0%
Classic/ Core brand								Over 40%	-ve 20%- 25%	+ve MSD	+ve MSD	+ve MSD				
Kids								Over 70%	-ve LSD	Over 30%	Over 30%	Over 20%				
Fusion								Over 100%	+ve MSD	Over 70%	Over 50%	Over 50%				
Online								Over 70%	160%	Over 80%	Over 90%	70%-80%				
Other brands							30%-35%	25%-30%	-ve HSD	25%-30%	50%-55%	55%-60%				
Descente				Over 100%	Over 100%	Over 90%	50%	50%	+ve Mid- teens	Over 60%	90%	Over 80%				
Kolon						15%	20%	20%	-ve High- teens	+ve LSD	20%-25%	30%-40%				
Li Ning group's SSSG	+ve Low- teens	+ve HSD	+ve Low- teens	+ve Mid- teens	+ve Mid- teens	+ve Mid- teens	+ve High- teens	+ve Low- twenties	n/a	-ve MSD	+ve LSD					
Direct retail	+ve Low- teens	+ve HSD	+ve HSD	+ve MSD	+ve HSD	+ve Low- teens	+ve Low- teens	+ve High- teens	n/a	-ve High- teens	-ve MSD					
Wholesales	+ve MSD	+ve LSD	+ve HSD	+ve MSD	+ve Low- teens	+ve Low- teens	+ve Low- teens	+ve Mid- teens	n/a	-ve Low- teens	-ve MSD					
E- Commerce	+ve High	+ve Mid- 30%	+ve High 30%	+ve Mid 50%	+ve High 30%	+ve Mid 30%	+ve Mid 50%	+ve Low 40%	+ve Low- teens	+ve Mid 20%	+ve High 30%					
Li Nino manuale matellica	TVE Mid-	+ve Low-		+ve High-	+ve Low	+ve Low	+ve Low	+ve Mid	-ve High-		+ve MSD	0.00/	24.00/	0.00/	7.00/	F 00/
Li Ning group's retail sa	teens	teens	teens	teens	20%-25%	20%-25%	30%-35%	30%-40%	teens	-ve MSD	+ve M2D	8.0%	34.0%	9.0%	7.0%	5.0%
Direct retail	Low 20%-	+ve Mid-	+ve Mid-	+ve HSD	+ve Low-	+ve HSD	+ve Mid-	+ve High-	-ve Mid	-ve Low-	Flat					
Direct rotali	30%	teens	teens		teens		teens	teens	30%	teens						
Wholesales	+ve MSD	+ve MSD	+ve Low- teens	+ve Low- teens	+ve Low 20%-25%	+ve Mid- 20%	+ve Mid- 30%	+ve Low 40%	-ve High- teens	-ve HSD	-ve LSD					
E- Commerce	+ve High 30%	+ve High 30%	+ve Low 30%	+ve Mid 50%	+ve Low 40%	+ve High 20%	+ve Low 50%	+ve Low 40%	+ve Low- teens	+ve High 20%	+ve Low 40%					
	+ve Low-	+ve Mid-			+ve Low-			+ve Low-	toons	2070	4070					
Xtep's SSSG	teens	teens	teens	teens	teens	teens	10%	teens								
Xtep's retail sales					Over 20%	Over 20%	20%	Over 20%	-ve 20%- 25%	-ve LSD	+ve MSD	+ve HSD	31.0%	4.0%	2.0%	0.0%
361 Degrees' SSSG	+ve HSD	+ve HSD	+ve MSD	Flat	+ve LSD	+ve LSD	+ve LSD	+ve LSD								
361 Degree's retail sale	S								-ve 20%- 25%	-ve Low- teens	-ve HSD	+ve LSD				
Pou Sheng's SSSG	10.1%	2.2%	8.9%	8.7%	8.4%	4.2%	6.0%	1.9%	-32.5%	-17.8%						
Pou Sheng's sales	17.7%	17.7%	24.4%	22.0%	19.9%	18.9%	21.9%	19.1%	-25.1%	0.3%	-0.3%	1.0%	29.0%	2.0%	0.0%	-3.0%
Dong Xiang's SSSG	+ve Mid to High	-ve Mid to High	+ve MSD	+ve LSD	-ve LSD	+ve MSD	+ve Mid to High	+ve Mid to High	-ve Low- Mid SD	-ve Mid SD	+ve Low- Mid SD					
Direct retail	+ve HSD	Flat	+ve Low- teens	+ve HSD	Flat	+ve LSD	+ve HSD	+ve Low- teens	-ve LSD	-ve Low to Mid-teens	-ve Low- Mid SD					
E- Commerce					+ve 35%- 45%	+ve 30%- 35%	+ve 55%- 60%	+ve 40%- 45%	-ve Low- teens	+ve 30%- 35%	+ve 30%- 35%					
					- 7	/ -				/ -	/ -					

Source: Company data, CMBIS estimates, *Nike's year end is in May (e.g. 4Q18 calendar year = 2Q19 fiscal year = Sep-Nov 2018)




Focus Charts

Figure 2: Domestic brands retail sales growth



Source: Company data, CMBIS estimates

Figure 3: Foreign brands retail sales growth



Source: Company data, CMBIS estimates

Figure 4: New product - Tiancheng series/ 天乘系列



Source: Company data, CMBIS estimates

Figure 5: New product - Tiancheng series/ 天乘系列



Source: Company data, CMBIS estimates

Figure 6: Xtep's new flagship store in Shenzhen



Source: Company data, CMBIS estimates

Figure 7: Xtep's new flagship store in Shenzhen



Source: Company data, CMBIS estimates



Figure 8: Xtep's performance during double 11

Figure 9: Xtep's performance during double 11



 件单价
 尖货占比

 10%+
 300%+

 不只有更好价格,还有更好货品

 Z世代占比超
 会员增长


 53%+
 62%+

 不仅更年轻,而且更招人喜欢

Source: Company data, CMBIS estimates

Source: Company data, CMBIS estimates

Figure 10: Xtep's marketing during the Double 11









Source: Bloomberg, CMBIS estimates, leaders include Anta, Li Ning, Nike, Adidas and Lulu Lemon



Earnings revision

Figure 11: Earnings revision

		New			Old			Diff (%)	
RMB mn	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E
Revenue	8,109	9,252	10,204	8,309	9,299	10,131	-2.4%	-0.5%	0.7%
Gross profit	3,222	3,735	4,214	3,331	3,777	4,158	-3.3%	-1.1%	1.3%
EBIT	881	1,081	1,320	887	1,042	1,254	-0.6%	3.8%	5.3%
Net profit att.	446	617	810	449	586	766	-0.7%	5.3%	5.8%
Diluted EPS (RMB)	0.179	0.248	0.325	0.180	0.235	0.307	-0.7%	5.3%	5.8%
Gross margin	39.7%	40.4%	41.3%	40.1%	40.6%	41.0%	-0.4ppt	-0.2ppt	0.3ppt
EBIT margin	10.9%	11.7%	12.9%	10.7%	11.2%	12.4%	0.2ppt	0.5ppt	0.6ppt
Net profit att. margin	5.5%	6.7%	7.9%	5.4%	6.3%	7.6%	0.1ppt	0.4ppt	0.4ppt

Source: Company data, CMBIS estimates


Figure 12: CMBIS estimates vs consensus

		CMBIS			Consensus			Diff (%)	
RMB mn	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E
Revenue	8,109	9,252	10,204	8,288	9,527	10,836	-2.2%	-2.9%	-5.8%
Gross profit	3,222	3,735	4,214	3,317	3,926	4,515	-2.9%	-4.9%	-6.7%
EBIT	881	1,081	1,320	867	1,149	1,388	1.7%	-5.9%	-4.9%
Net profit att.	446	617	810	460	673	823	-3.0%	-8.4%	-1.5%
Diluted EPS (RMB)	0.179	0.248	0.325	0.192	0.270	0.322	-6.6%	-8.3%	1.0%
Gross margin	39.7%	40.4%	41.3%	40.0%	41.2%	41.7%	-0.3ppt	-0.8ppt	-0.4ppt
EBIT margin	10.9%	11.7%	12.9%	10.5%	12.1%	12.8%	0.4ppt	-0.4ppt	0.1ppt
Net profit att. margin	5.5%	6.7%	7.9%	5.6%	7.2%	8.0%	-0.1ppt	-0.6ppt	0ppt

Source: Company data, CMBIS estimates




Figure 13: Anta, Li Ning and Xtep's forward 2 years P/E



Source: Bloomberg, CMBIS estimates

Figure 14: Forward 2 years P/E - Xtep's discounts to Anta and Li Ning



Source: Bloomberg, CMBIS estimates



Valuation

Figure 15: Peers valuation table

			12m TP	Price	Up/ Down-	Mkt. Cap	Year	P/E	(x)	P/B	(x)	ROE (%)	3yrs PEG (x)	Yield (%)
Company	Ticker	Rating	(LC)	(LC)	side	(HK\$mn)	End	FY1E	FY2E	FY1E	FY2E	FY1E		FY1E
H shares Spo	rtswear													
Xtep Intl	1368 HK	BUY	5.09	3.81	34%	9,704	Dec-19	19.0	13.8	1.1	1.1	7.4	7.6	3.2
Anta Sports	2020 HK	BUY	150.98	129.50	17%	350,081	Dec-19	56.1	37.3	12.2	9.8	23.0	2.3	0.6
Li Ning	2331 HK	BUY	36.52	50.80	-28%	126,448	Dec-19	65.9	47.7	12.4	10.3	19.8	2.7	0.4
361 Degrees	1361 HK	NR	n/a	1.24	n/a	2,564	Dec-19	5.3	4.9	0.3	0.3	5.8	1.0	6.7
Topsports	6110 HK	NR	n/a	11.42	n/a	70,818	Feb-20	23.9	19.1	5.6	4.8	36.9	1.6	5.8
Pou Sheng	3813 HK	NR	n/a	1.74	n/a	9,321	Dec-19	19.9	7.0	1.0	0.9	5.6	1.0	0.6
China DX	3818 HK	NR	n/a	0.77	n/a	4,532	Mar-20	4.4	4.2	0.3	0.3	11.8	0.2	12.4
							Avg.	27.8	19.1	4.7	3.9	15.8	2.3	4.2
							Med.	19.9	13.8	1.1	1.1	11.8	1.6	3.2
International S	<u>portswear</u>													
Nike Inc	NKE US	NR	n/a	140.72	n/a	1,720,131	May-20	46.5	36.4	21.5	18.8	28.3	1.2	0.7
Adidas	ADS GY	NR	n/a	281.80	n/a	529,613	Dec-19	128.4	32.6	7.9	6.9	6.6	27.2	8.0
Puma	PUM GY	NR	n/a	87.94	n/a	124,378	Dec-19	162.0	44.9	6.7	6.1	3.8	9.4	0.2
Under Armour	UAA US	NR	n/a	18.09	n/a	58,950	Dec-19	n/a	145.9	5.4	5.1	(41.3)	0.0	0.0
Lululemon	LULU US	NR	n/a	344.50	n/a	348,157	Feb-20	75.0	51.2	18.6	15.5	29.2	4.3	0.0
Skechers	SKX US	NR	n/a	36.66	n/a	44,672	Dec-19	50.8	17.1	2.2	1.9	4.6	11.3	0.0
Vf Corp	VFC US	NR	n/a	83.91	n/a	253,745	Mar-21	63.5	28.5	13.7	13.0	(1.3)	2.4	2.3
Columbia	COLM US	NR	n/a	92.80	n/a	47,643	Dec-19	65.4	25.7	3.4	3.0	7.3	(20.4)	0.3
Wolverine	WWW US	NR	n/a	31.76	n/a	20,211	Dec-19	35.3	15.5	3.2	2.8	4.2	2.4	1.3
Mizuno Corp	8022 JP	NR	n/a	2038.00	n/a	4,046	Mar-20	n/a	15.6	0.6	0.6	1.9	0.0	2.5
Asics Corp	7936 JP	NR	n/a	1861.00	n/a	26,392	Dec-19	n/a	42.1	2.5	2.5	(2.2)	0.0	1.3
							Avg.	78.4	41.4	7.8	6.9	3.7	3.4	8.0
							Med.	64.4	32.6	5.4	5.1	4.2	2.4	0.7

Source: Bloomberg, CMBIS estimates



Assumptions

Figure 16: Xtep's key assumptions

Major assumptions	FY18A	FY19A	FY20E	FY21E	FY22E
Sales by segment (RMB mn)					
Shoes	3,925	4,653	4,823	5,584	6,209
Apparels	2,327	3,344	3,110	3,484	3,797
Accessories	131	185	176	185	198
Total	6,383	8,183	8,109	9,252	10,204
Sales by segment growth (%)					
Shoes	20.5%	18.6%	3.7%	15.8%	11.2%
Apparels	32.2%	43.7%	-7.0%	12.0%	9.0%
Accessories	36.6%	41.0%	-5.0%	5.0%	7.0%
Total	24.8%	28.2%	-0.9%	14.1%	10.3%
Sales by segment (RMB mn)					
Mass market	6,383	7,707	7,292	8,127	8,860
Athleisure	0	466	769	908	1,044
Professional sports	0	10	48	217	301
Total	6,383	8,183	8,109	9,252	10,204
Sales by segment growth (YoY)					
Mass market	24.8%	20.7%	-5.4%	11.4%	9.0%
Athleisure	n/a	n/a	65.0%	18.1%	14.9%
Professional sports	n/a	n/a	379.0%	349.2%	38.4%
Total	24.8%	28.2%	-0.9%	14.1%	10.3%
Sales network					
Xtep	5,580	5,279	4,962	5,012	5,112
Xtep kids	450	850	833	891	980
Oversea stores	200	250	250	250	300
Total	6,230	6,379	6,045	6,153	6,393
GP margins	44.3%	43.4%	39.7%	40.4%	41.3%
Opex breakdown					
A&P / sales	15.2%	14.4%	12.1%	11.8%	11.6%
Staff costs/ sales	11.6%	11.0%	12.3%	12.1%	12.6%
R&D / sales	2.6%	2.4%	2.8%	2.6%	2.4%
D&A / sales	1.4%	1.7%	2.2%	2.1%	1.9%
Provisions (write backs) / sales	-0.8%	-0.9%	-0.3%	0.0%	0.0%
Rental / sales	0.3%	0.1%	0.7%	0.9%	1.1%
Selling & distribution costs / sales	21.3%	21.0%	20.1%	20.0%	19.9%
Admin expenses / sales	9.8%	11.1%	12.3%	11.0%	10.6%
Total	31.0%	32.1%	32.4%	31.0%	30.5%
OP margins	16.4%	15.1%	10.9%	11.7%	12.9%
Effective tax rate	31.4%	34.8%	38.0%	33.0%	32.0%
Net profit att. margins	10.3%	8.9%	5.5%	6.7%	7.9%
Net profit att. growth (%)	60.9%	10.8%	-38.7%	38.3%	31.4%

Source: Company data, CMBIS estimates



Financial Summary

Income statement						Cash flow summary					
YE 31 Dec (RMB mn)	FY18A	FY19A	FY20E	FY21E	FY22E	YE 31 Dec (RMB mn)	FY18A	FY19A	FY20E	FY21E	FY22E
Revenue	6,383	8,183	8,109	9,252	10,204	EBIT	1,044	1,234	881	1,081	1,320
Footwear	3,925	4,653	4,823	5,584	6,209	D & A	60	185	317	330	340
Apparel	2,327	3,344	3,110	3,484	3,797	Change in working capital	(513)	36	338	(292)	(249)
Accessories	131	185	176	185	198	Income tax paid	(309)	(334)	(277)	(306)	(385)
						Others	(128)	(343)	(115)	(94)	(99)
Cost of goods sold	(3,555)	(4,632)	(4,887)	(5,517)	(5,990)	Net cash from operating	154	778	1,144	718	928
Gross profit	2,828	3,550	3,222	3,735	4,214						
Other income	196	308	284	213	219	Capex & investments	(72)	(97)	(203)	(139)	(153)
						Associated companies	(1)	(35)	-	-	-
Operating expenses	(1,980)	(2,625)	(2,624)	(2,866)	(3,113)	Interest received	-	-	-	-	-
S & D costs	(1,357)	(1,718)	(1,627)	(1,849)	(2,036)	Others	(208)	(1,913)	-	-	-
Admin exp.	(456)	(711)	(770)	(777)	(832)	Net cash from investing	(281)	(2,045)	(203)	(139)	(153)
R&D	(166)	(195)	(227)	(241)	(245)						
Other operating expenses	-	-	-	-	-	Equity raised	(31)	1,187	-	-	-
EBIT	1,044	1,234	881	1,081	1,320	Net change in bank loans	(10)	386	-	-	-
						Dividend paid	(459)	(436)	(331)	(332)	(443)
Finance costs, net	(68)	(111)	(115)	(94)	(99)	Others	(11)	(98)	-	-	-
JVs & associates	-	(2)	(36)	(60)	(18)	Net cash from financing	(511)	1,039	(331)	(332)	(443)
Exceptional	-	-	-	-	-						
Pre-tax profit	976	1,121	730	927	1,204	Net change in cash	(637)	(227)	610	248	332
						Beginning cash balance	3,832	3,196	2,970	3,579	3,827
Income tax	(306)	(390)	(277)	(306)	(385)	Exchange difference	1	1	-	-	-
Less: Minority interests	13	4	7	5	8	Cash at the end of the year	3,196	2,970	3,579	3,827	4,159
Net profit	657	728	446	617	810	-					

YE 31 Dec (RMB mn)	FY18A	FY19A	FY20E	FY21E	FY22E	YE 31 Dec	FY18A	FY19A	FY20E	FY21E	FY22E
Non-current assets	1,139	3,057	2,906	2,655	2,451	Sales mix (%)					
Fixed asset	641	662	787	836	890	Footwear	61.5	56.9	59.5	60.4	60.9
Intangible assets & goodwill	105	1,738	1,499	1,258	1,017	Apparel	36.5	40.9	38.4	37.7	37.2
Prepaid lease payments	279	104	104	104	104	Accessories	2.1	2.3	2.2	2.0	1.9
Interest in joint ventures	114	197	161	101	84		-	-	-	-	-
Other non-current assets	-	356	356	356	356	Total	100.0	100.0	100.0	100.0	100.0
Current assets	8,060	9,266	9,716	10,600	11,451	P&L ratios (%)					
Cash and cash equivalents	3,196	2,970	3,579	3,827	4,159	Gross margin	44.3	43.4	39.7	40.4	41.3
Inventories	836	1,046	1,138	1,285	1,395	Operating margin	16.4	15.1	10.9	11.7	12.9
Trade and other receivables	2,115	2,910	2,666	3,042	3,355	Pre-tax margin	15.3	13.7	9.0	10.0	11.8
Prepayments	727	818	810	925	1,020	Net margin	10.3	8.9	5.5	6.7	7.9
Other current assets	1,186	1,522	1,522	1,522	1,522	Effective tax rate	31.4	34.7	36.2	31.0	31.5
Current liabilities	3,278	3,671	3,849	4,193	4,463	Balance sheet ratios					
Bank loans	1,483	1,086	1,086	1,086	1,086	Current ratio (x)	2.5	2.5	2.5	2.5	2.6
Trade payables	879	1,420	1,607	1,814	1,969	Quick ratio (x)	2.2	2.2	2.2	2.2	2.3
Accruals & other payables	861	981	972	1,109	1,223	Cash ratio (x)	1.0	0.8	0.9	0.9	0.9
Tax payables	54	115	115	115	115	Inventory turnover days	86	82	85	85	85
Others	1	69	69	69	69	Trade receivables days	121	130	120	120	120
						Trade payables days	90	112	120	120	120
Non-current liabilities	590	1,691	1,691	1,691	1,691	Total debt / total equity ratio (%)	36	34	33	32	30
Bank loans	461	1,269	1,269	1,269	1,269	Net debt / equity ratio (%)	Net cash				
Deferred income	-	-	-	-	-	Returns (%)					
Deferred tax	107	280	280	280	280	ROE	12.3	10.5	6.3	8.4	10.5
Others	22	142	142	142	142	ROA	7.1	5.9	3.5	4.7	5.8
						Per share					
Minority Interest	-	-	7	11	20	EPS (RMB)	0.30	0.30	0.18	0.25	0.33
Total net assets	5,331	6,960	7,075	7,360	7,728	DPS (RMB)	0.18	0.18	0.11	0.15	0.20
Shareholders' equity	5,331	6,960	7,075	7,360	7,728	BVPS (RMB)	2.40	2.79	2.84	2.95	3.10



Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIS Ratings

BUY
Stock with potential return of over 15% over next 12 months
SELL
Stock with potential return of +15% to -10% over next 12 months
SELL
Stock with potential loss of over 10% over next 12 months

NOT RATED : Stock is not rated by CMBIS

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months

MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months

UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Securities Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Securities Limited ("CMBIS") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIS does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIS recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIS, solely for the purpose of supplying information to the clients of CMBIS and/or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIS nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIS has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIS provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIS may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIS may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIS may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIS may have a conflict of interest that could affect the objectivity of this report and CMBIS will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIS. Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc...) of the Order, and may not be provided to any other person without the prior written consent of CMBIS.

For recipients of this document in the United States

CMBIS is not a registered broker-dealer in the United States. As a result, CMBIS is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.